Hormones and Hormone Antagonists: Mechanisms of Action in Carcinogenesis of Endometrial and Breast Cancer

 

 Buy Article Permissions and Reprints

Proliferation of breast and endometrial cells is under the control of ovarian steroid hormones (SHs) such as oestrogen and progesterone. They mediate diverse physiological functions via interaction with nuclear-localised steroid hormone receptors (HRs). The SH receptor complex modifies the expression of SH-regulated genes by binding to conserved binding sites in their promoter region or through cross-talk with other transcription factors. In non-malignant tissues, HRs are in balance with other factors regulating proliferation, differentiation and apoptosis. While dysfunction of the regulatory mechanisms is a part of malignant transformation, functional SH receptors can promote growth of SH-responsive tumours. Therefore, anti-hormones that block the interaction of steroid hormones with the SH receptor are useful tools for the treatment of SH-responsive carcinomas. However, a portion of ER-positive breast cancers and most endometrial cancers do not respond to anti-oestrogens and continued treatment results in hormone resistance, mostly without loss of the ER. This review focuses on the mechanisms of action of hormones and anti-hormones in breast and endometrial carcinomas.

References

• 1 Beatson G T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.  Lancet. 1896;  2 104-207
  PubMedGoogle Scholar
• 2 Lacassagne A. Apparition de cancers de la mamelle chez la souris mâle, soumise à des injections de folliculine C.  R Acad Sci. 1932;  195 630-632
  PubMedGoogle Scholar
• 3 Lupulescu A. Oestrogene use and risk: a review.  Exp Clin Endocrin Diabetes. 1993;  101 204-214
  PubMedGoogle Scholar
• 4 Beckmann M W, Niederacher D, Schnurch H G, Gusterson B A, Bender H G. Multistep carcinogenesis of breast cancer and tumour heterogeneity.  J Mol Med. 1997;  75 429-439
  CrossrefPubMedGoogle Scholar
• 5 Cohen S M, Ellwein L B. Genetic errors, cell proliferation, and carcinogenesis.  Cancer Res. 1991;  51 6493-6505
  PubMedGoogle Scholar
• 6 Devilee P, Cornelisse C J. Somatic genetic changes in human breast cancer.  Biochim Biophys Acta. 1996;  1198 113-130
  PubMedGoogle Scholar
• 7 Goldhirsch A, Glick J H, Gelber R D, Senn H J. Meeting highlights: International consensus panel on the treatment of primary breast cancer.  J Natl Cancer Inst. 1998;  90 1601-1608
  PubMedGoogle Scholar
• 8 Osborne C K. Tamoxifen in the treatment of breast cancer.  N Engl J Med. 1998;  339 1609-1618
  CrossrefPubMedGoogle Scholar
• 9 Cook L S, Weiss N S, Schwartz S M, White E, McKnight B, Moore D E, Daling J R. Population-based study tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer.  J Natl Cancer Inst. 1995;  87 1359-1364
  PubMedGoogle Scholar
• 10 Cuenca R E, Giachino J, Arredondo M A, Hempling R, Edge S B. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.  Cancer. 1996;  77 2058-2063
  CrossrefPubMedGoogle Scholar
• 11 Delmas P D, Bjarnason N H, Mitlak B H, Ravoux A C, Shah A S, Huster W J, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women (see comments).  N Engl J Med. 1997;  337 1641-1647
  CrossrefPubMedGoogle Scholar
• 12 . Early Breast Cancer Trialists’ Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials.  Lancet. 1998;  351 1451-1467
  CrossrefPubMedGoogle Scholar
• 13 Fisher B, Costantino J P, Wickerham D L, Redmond C K, Kavanah M, Cronin W M, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst. 1998;  90 1371-1388
  CrossrefPubMedGoogle Scholar
• 14 Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.  J Clin Oncol. 1998;  16 2018-2024
  PubMedGoogle Scholar
• 15 Smith D C, Prentice R, Thompson D J, Herrmann W L. Association of exogenous oestrogen and endometrial carcinoma.  N EngI J Med. 1975;  293 1164-1167
  PubMedGoogle Scholar
• 16 . The Writing Group for the PEPI Trial . Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal oestrogen/progestin interventions (PEPI) trial.  JAMA. 1996;  275 370-375
  CrossrefPubMedGoogle Scholar
• 17 Voigt L F, Weiss I SIS, Chu J, Daling J R, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer.  Lancet. 1991;  338 274-277
  CrossrefPubMedGoogle Scholar
• 18 Van Leeuwen F E, Rokus M A. The role of exogenous hormones in the epidemiology of breast ovarian and endometrial breast cancer.  Eur J Cancer Clin Oncol. 1989;  25 1961-1972
  PubMedGoogle Scholar
• 19 Belchetz P E. Hormonal treatment of postmenopausal women.  N Engl J Med. 1994;  330 1062-1071
  CrossrefPubMedGoogle Scholar
• 20 Colditz G A, Hankinson S E, Hunter D J, Willett W C, Manson J E, Stampfer M J, Hennekens C, Rosner B, Speizer F E. The use of oestrogens and progestins and the risk of breast cancer in postmenopausal women.  N Engl J Med. 1995;  332 1589-1593
  CrossrefPubMedGoogle Scholar
• 21 . Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer.  Lancet. 1997;  350 1047-1059
  CrossrefPubMedGoogle Scholar
• 22 Roy J A, Sawka C A, Pritchard K I. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?.  J Clin Oncol. 1996;  14 997-1006
  PubMedGoogle Scholar
• 23 Peluso J J. Placing Progesterone in the apoptotic pathway.  TEM. 1997;  8 267-271
  PubMedGoogle Scholar
• 24 Ciocca D R, Vargas Roig L M, Fanelli M A. Oestrogen receptors in the human femal genital tract in normal and pathological conditions.  Biocell. 1994;  18 1-21
  PubMedGoogle Scholar
• 25 Kokawa K, Shikone T, Nakano R. Apoptosis in the human uterine endometrium during the menstrual cycle.  J Clin Endocrinol Metab. 1996;  181 4144-4147
  PubMedGoogle Scholar
• 26 Beckmann M W, Hanstein B, Niederacher D, Jap D, Kuschel B, Bender M G. Mechanisms of ovarian steroid hormones and antioestrogens in the development of carcinomas of the breast and endometrium.  Geburtsh Frauenheilk. 2000;  60 71-76
  PubMedGoogle Scholar
• 27 Kahn S A, Rogers M AM, Khurana K K, Meguid M M, Numan P J. Oestrogen receptor expression in benign breast epithelium and breast cancer risk.  J Nat Cancer Inst. 1997;  189 37-42
  PubMedGoogle Scholar
• 28 Beckmann M W, Niederacher D, Bender H G. Mechanisms of steroid hormone action and resistance in endometrial and breast cancer.  Eur J Cancer Prev. 1998;  7 S25-S28
  PubMedGoogle Scholar
• 29 Jordan V C. Anti-oestrogenic action of raloxifene and tamoxifen: today and tomorrow.  J Natl Cancer Inst. 1998;  90 967-971
  CrossrefPubMedGoogle Scholar
• 30 Evans R M. The steroid and thyroid hormone receptor superfamily.  Science. 1988;  240 889-895
  CrossrefPubMedGoogle Scholar
• 31 Ming J T, O’Mally. Molecular mechanisms of action of steroid/thyroid receptor superfamily members.  Annu Rev Biochem. 1994;  63 451-486
  CrossrefPubMedGoogle Scholar
• 32 Kuiper G G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J A. Cloning of a novel receptor expressed in rat prostate and ovary.  Proc Natl Acad Sci USA. 1996;  93 5925-5930
  CrossrefPubMedGoogle Scholar
• 33 Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human oestrogen receptor.  FEBS Left. 1996;  392 49-53
  CrossrefPubMedGoogle Scholar
• 34 Tremblay G B, Tremblay A, Copeland N G, Gilbert D J, Jenkins N A, Labrie F, Giguere V. Cloning, chromosomal localization, and functional analysis of the murine oestrogen receptor beta.  Mol Endocrinol. 1997;  11 353-365
  CrossrefPubMedGoogle Scholar
• 35 Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human oestrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro.  Biochem Biophys Res Commun. 1998;  243 122-126
  PubMedGoogle Scholar
• 36 Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot.  Cell. 1995;  83 851-857
  CrossrefPubMedGoogle Scholar
• 37 Parker M G. Steroid and related receptors.  Curr Opin Cell Biol. 1993;  5 499-504
  CrossrefPubMedGoogle Scholar
• 38 May F E, Westley B R. Oestrogen regulated messenger RNAs in human breast cancer cells.  Biomed Pharmacother. 1995;  49 400-414
  CrossrefPubMedGoogle Scholar
• 39 Gaub M P, Bellard M, Scheurer I, Chambon P, Sassone C P. Activation of the ovalbumine gene by the estorgen receptor involves the fos jun complex.  Cell. 1996;  63 1267-1276
  PubMedGoogle Scholar
• 40 Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey J M, Rochefort H, Chalbos D. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells.  Mol Endocrinol. 1998;  12 973-985
  CrossrefPubMedGoogle Scholar
• 41 Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Oestrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer.  J Biol Chem. 1994;  269 16 433-16 442
  PubMedGoogle Scholar
• 42 Paech K, Webb P, Kuiper G G, Nilsson S, Gustafsson J, Kushner P J, Scanlan T S. Differential ligand activation of oestrogen receptors ERalpha and ERbeta at AP1 sites.  Science. 1997;  277 1508-1510
  CrossrefPubMedGoogle Scholar
• 43 Lee S K, Kim H J, Kim J W, Lee J W. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53.  Mol Endocrinol. 1999;  13 1924-1933
  CrossrefPubMedGoogle Scholar
• 44 Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S C, Heyman R A, Rose D W, Glass C K, Rosenfeld M G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.  Cell. 1996;  85 403-414
  CrossrefPubMedGoogle Scholar
• 45 Gottlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action.  J Mol Med. 1998;  76 480-489
  CrossrefPubMedGoogle Scholar
• 46 Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Oestrogen receptor-associated proteins: possible mediators of hormone-induced transcription.  Science. 1994;  264 1455-1458
  PubMedGoogle Scholar
• 47 Horwitz K B, Jackson T A, Bain D L, Richer J K, Takimoto G S, Tung L. Nuclear receptor coactivators and corepressors.  Mol Endocrinol. 1996;  10 1167-1177
  CrossrefPubMedGoogle Scholar
• 48 Leo C, Chen J D. The SRC family of nuclear receptor coactivators.  Gene. 2000;  245 1-11
  CrossrefPubMedGoogle Scholar
• 49 Onate S A, Tsai S Y, Tsai M J, O’Malley B W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.  Science. 1995;  270 1354-1357
  PubMedGoogle Scholar
• 50 Anzick S L, Kononen J, Walker R L, Azorsa D O, Tanner M M, Guan X Y, Sauter G, Kallioniemi O P, Trent J M, Meltzer P S. A1131, a steroid receptor coactivator amplified in breast and ovarian cancer.  Science. 1997;  277 965-968
  CrossrefPubMedGoogle Scholar
• 51 Li H, Gomes P J, Chen J D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.  Proc Nati Acad Sci USA. 1997;  94 8479-8484
  CrossrefPubMedGoogle Scholar
• 52 Voegel J J, Heine M J, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.  Embo J. 1996;  15 3667-3675
  PubMedGoogle Scholar
• 53 Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M. p300 is a component of an oestrogen receptor coactivator complex.  Proc Natl Acad Sci USA. 1996;  93 11 540-11 545
  PubMedGoogle Scholar
• 54 Torchia J, Rose D W, Inostroza J, Kamei Y, Westin S, Glass C K, Rosenfeld M G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function.  Nature. 1997;  387 677-684
  CrossrefPubMedGoogle Scholar
• 55 Wehling M. Specific, nongenomic actions of steroid hormones.  Annu Rev Physiol. 1997;  59 365-393
  CrossrefPubMedGoogle Scholar
• 56 Collins P, Webb C. Oestrogen hits the surface.  Nat Med. 1999;  5 1130-1131
  PubMedGoogle Scholar
• 57 Benten W P, Lieberherr M, Giese G, Wrehlke C, Stamm O, Sekeris C E, Mossmann H, Wunderlich F. Functional testosterone receptors in plasma membranes of T cells.  Faseb J. 1999;  13 123-133
  PubMedGoogle Scholar
• 58 Wehling M, Neylon C B, Fullerton M, Bobik A, Funder J W. Nongenomic effects of aldosterone on intracellular Ca²⁺ in vascular smooth muscle cells.  Circ Res. 1995;  76 973-979
  PubMedGoogle Scholar
• 59 Teschemacher A, Zeise M L, Holsboer F, Zieglgansberger W. The neuroactive steroid 5 alpha-tetrahydrodeoxycorticosterone increases GABAergic postsynaptic inhibition in rat neocortical neurons in vitro. .  J Neuroendocrinol. 1995;  7 233-240
  PubMedGoogle Scholar
• 60 Pietras R J, Szego C M. Endometrial cell calcium and oestrogen action.  Nature. 1975;  253 357-359
  PubMedGoogle Scholar
• 61 Mermelstein P G, Becker J B, Surmeier D J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor.  J Neurosci. 1996;  16 595-604
  PubMedGoogle Scholar
• 62 Morley P, Whitfield J F, Vanderhyden B C, Tsang B K, Schwartz J L. A new, nongenomic oestrogen action: the rapid release of intracellular calcium.  Endocrinology. 1992;  131 1305-1312
  CrossrefPubMedGoogle Scholar
• 63 Valverde M A, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde M I, Mann G E, Vergara C, Latorre R. Acute activation of maxi-K channels (hSlo) by estradiol binding to the beta subunit.  Science. 1999;  285 1929-1931
  CrossrefPubMedGoogle Scholar
• 64 Chen Z, Yuhanna I S, Galcheva-Gargova Z, Karas R H, Mendelsohn M E, Shaul P W. Oestrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by oestrogen (published erratum appears in J Clin Invest 1999 May; 103 (9): 1363).  J Clin Invest. 1999;  103 401-406
  CrossrefPubMedGoogle Scholar
• 65 Norfleet A M, Thomas M L, Gametchu B, Watson C S. Oestrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry.  Endocrinology. 1999;  140 3805-3814
  CrossrefPubMedGoogle Scholar
• 66 Razandi M, Pedram A, Greene G L, Levin E R. Cell membrane and nuclear oestrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells.  Mol Endocrinol. 1999;  13 307-319
  CrossrefPubMedGoogle Scholar
• 67 Le Mellay V, Lasmoles F, Lieberherr M. Galpha(q/11) and gbetagamma proteins and membrane signaling of calcitriol and estradiol.  J Cell Biochem. 1999;  75 138-146
  CrossrefPubMedGoogle Scholar
• 68 Improta-Brears T, Whorton A R, Codazzi F, York J D, Meyer T, McDonnell D ID. Oestrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium.  Proc Natl Acad Sci USA. 1999;  96 4686-4691
  CrossrefPubMedGoogle Scholar
• 69 Lobenhofer EK Huper G, lglehart J D, Marks J R. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents oestrogeninduced mitogenesis.  Cell Growth Differ. 2000;  11 99-110
  PubMedGoogle Scholar
• 70 Shyamala G, Barcellos-Hoff M H, Toft D, Yang X. In situ localization of progesterone receptors in normal mouse mammary glands: absence of receptors in the connective and adipose stroma and a heterogeneous distribution in the epithelium.  J Steroid Biochem Mol Biol. 1997;  63 251-259
  CrossrefPubMedGoogle Scholar
• 71 . Early Breast Cancer Trialists’ Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women.  Lancet. 1992;  339 71-85
  PubMedGoogle Scholar
• 72 . Early Breast Cancer Trialists’ Collaborative Group . Ovarian ablation in early breast cancer - overview of the randomised trials.  Lancet. 1996;  348 1189-1196
  CrossrefPubMedGoogle Scholar
• 73 Curtis R E, Boice J D Jr, Shriner D A, Hankey B F, Fraumeni J F Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer.  J Natl Cancer Inst. 1996;  88 832-834
  PubMedGoogle Scholar
• 74 Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann M W, Haussinger D. CD95 ligand expression in dedifferentiated breast cancer.  J Pathol. 1999;  189 378-386
  PubMedGoogle Scholar
• 75 Dati C, Antoniofti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by oestrogens in human breast cancer cells.  Oncogene. 1990;  5 1001-1006
  PubMedGoogle Scholar
• 76 Gudas J M, Nguyen H, Li T, Cowan K H. Hormone-dependent regulation of BRCA1 in human breast cancer cells.  Cancer Res. 1995;  55 4561-4565
  PubMedGoogle Scholar
• 77 Zwijsen R M, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides R J. CDK-independent activation of oestrogen receptor by cyclin D1.  Cell. 1997;  88 405-415
  CrossrefPubMedGoogle Scholar
• 78 Brzozowski A M, Pike A C, Dauter Z, Hubbard R, Bonn T, Engstrom O, Ohman L, Greene G L, Gustafsson J A, Cadquist M. Molecular basis of agonism and antagonism in the oestrogen receptor.  Nature. 1997;  16 753-758
  PubMedGoogle Scholar
• 79 Gelmann E P. Tamoxifen induction of apoptosis in oestrogen receptor-negative cancers: new tricks for an old dog?.  J Natl Cancer Inst. 1996;  88 224-226
  PubMedGoogle Scholar
• 80 Johnston S R, Haynes B P, Smith I E, Jarman M, Sacks N P, Ebbs S R, Dowsett M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.  Lancet. 1993;  342 1521-1522
  PubMedGoogle Scholar
• 81 Gottardis M M, Jordan V C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term anti-oestrogen administration.  Cancer Res. 1988;  148 5183-5187
  PubMedGoogle Scholar
• 82 Schwartz L B, Krey L, Demopoulos R, Goldstein S R, Nachtigall L E, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium.  Am J Obstet Gynecol. 1997;  176 129-137
  PubMedGoogle Scholar
• 83 Webb P, Lopez G N, Uht R M, Kushner P J. Tamoxifen activation of the oestrogen receptor/AP-1 pathway: potential origin for the cell-specific oestrogen-like effects of antioestrogens.  Mol Endocrinol. 1995;  9 443-456
  CrossrefPubMedGoogle Scholar

Prof. Dr. M. W. Beckmann

Department of Obstetrics and Gynaecology
Friedrich-Alexander Universität Erlangen

Universitätsstrasse 21
91054 Erlangen
Germany


Phone: + 49 (9131) 85 334 51